<DOC>
	<DOC>NCT02665312</DOC>
	<brief_summary>observational prospective study, designed for patients with colorectal cancer receiving for the first time 5-FU or capecitabine, with or without other chemotherapy combinations.</brief_summary>
	<brief_title>Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine</brief_title>
	<detailed_description>All patients enrolled will be evaluated for cardiovascular risk factors and, if resulted at cardiovascular risk, they will be submitted to cardiac examination and therapy optimization before starting chemotherapy. Patients will be evaluated with 12-lead ECG and blood sample for TnI and NT pro-BNP before start chemotherapy and on day 3 of chemotherapy during the first, second and third cycle. All patients developing cardiovascular events will be submitted to blood sample for TnI, NT-proBNP, hsTnI and cardiac examination.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Signed written informed consent Age â‰¥ 18 years Histologically confirmed adenocarcinoma of colon or rectum (any T, any N, any M) receiving for the first time 5FU or capecitabine, with or without other chemotherapy combinations Prior treatment with fluoropyrimidines Prior or concurrent chest radiotherapy Any prior or concurrent treatment with cardiotoxic drug Any serious or uncontrolled cardiovascular disease (defined by the specialist during cardiac examination, see section 6.3.2 for details )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cardiotoxicity</keyword>
	<keyword>fluoropyrimidine</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>